Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker MLYS
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Abigail P. Johnson | 4.46M | 5.1% | SCHEDULE 13G/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | FMR LLC | 4.46M | 5.1% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Brian Taylor Slingsby | 8.00M | 10.1% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Catalys Pacific, LLC | 8.00M | 10.1% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Catalys Pacific Fund GP, LP | 8.00M | 10.1% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Catalys Pacific Fund, LP | 8.00M | 10.1% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G | MLYS Mineralys Therapeutics, Inc. | Abigail P. Johnson | 5.02M | 6.3% | SCHEDULE 13G ↗ |
| Feb 5, 2026 | SCHEDULE 13G | MLYS Mineralys Therapeutics, Inc. | FMR LLC | 5.02M | 6.3% | SCHEDULE 13G ↗ |
| Jan 21, 2026 | SCHEDULE 13G | MLYS Mineralys Therapeutics, Inc. | BlackRock, Inc. | 4.11M | 5.2% | SCHEDULE 13G ↗ |
| Sep 8, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | Srinivas Akkaraju | 6.35M | 8.2% | SCHEDULE 13D/A ↗ |
| Sep 8, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | Samsara Opportunity Fund GP, LLC | 588,235 | 0.8% | SCHEDULE 13D/A ↗ |
| Sep 8, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | Samsara Opportunity Fund, L.P. | 588,235 | 0.8% | SCHEDULE 13D/A ↗ |
| Sep 8, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | Samsara BioCapital GP, LLC | 5.67M | 7.3% | SCHEDULE 13D/A ↗ |
| Sep 8, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | Samsara BioCapital, L.P. | 5.67M | 7.3% | SCHEDULE 13D/A ↗ |
| Sep 8, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 5.85M | 7.5% | SCHEDULE 13D/A ↗ |
| Sep 8, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | Rajeev Shah | 7.80M | 9.9% | SCHEDULE 13D/A ↗ |
| Sep 8, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | Peter Kolchinsky | 7.80M | 9.9% | SCHEDULE 13D/A ↗ |
| Sep 8, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | RA Capital Management, L.P. | 7.80M | 9.9% | SCHEDULE 13D/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Francois Xavier Mauron | 2.77M | 4.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Stephane Bergez | 2.77M | 4.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | BioDiscovery 6 FPCI | 2.77M | 4.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Andera Partners | 2.77M | 4.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Brian Taylor Slingsby | 8.98M | 13.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Catalys Pacific, LLC | 8.98M | 13.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Catalys Pacific Fund GP, LP | 8.98M | 13.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Catalys Pacific Fund, LP | 8.98M | 13.5% | SCHEDULE 13G/A ↗ |
| Mar 17, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | Srinivas Akkaraju | 5.74M | 9.1% | SCHEDULE 13D/A ↗ |
| Mar 17, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | Samsara BioCapital GP, LLC | 5.67M | 9.0% | SCHEDULE 13D/A ↗ |
| Mar 17, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | Samsara BioCapital, L.P. | 5.67M | 9.0% | SCHEDULE 13D/A ↗ |
| Mar 17, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 4.36M | 6.9% | SCHEDULE 13D/A ↗ |
| Mar 17, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | Rajeev Shah | 6.29M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 17, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | Peter Kolchinsky | 6.29M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 17, 2025 | SCHEDULE 13D/A (amended) | MLYS Mineralys Therapeutics, Inc. | RA Capital Management, L.P. | 6.29M | 9.9% | SCHEDULE 13D/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Adams Street Growth Equity Fund VII LP | 438,123 | 0.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Adams Street 2021 Direct Growth Equity Fund LP | 102,305 | 0.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Adams Street 2020 Direct Growth Equity Fund LP | 105,448 | 0.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Adams Street 2019 Direct Growth Equity Fund LP | 98,889 | 0.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Adams Street 2018 Direct Venture/Growth Fund LP | 176,038 | 0.4% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Adams Street 2017 Direct Venture/Growth Fund LP | 117,878 | 0.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Adams Street 2016 Direct Venture/Growth Fund LP | 91,126 | 0.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MLYS Mineralys Therapeutics, Inc. | Adams Street Partners, LLC | 1.13M | 2.3% | SCHEDULE 13G/A ↗ |
41 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:44 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances